Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 25.
doi: 10.1007/s12020-025-04325-5. Online ahead of print.

Factors influencing the initial glycemic efficacy of dorzagliatin, a novel glucokinase activator, in type 2 diabetes

Lijiao Chen  1 , Jing Zhang  2 , Xuelu Zhao  3 , Song Wen  1 , Ying Wang  4 , Ligang Zhou  5   6
Affiliations

Factors influencing the initial glycemic efficacy of dorzagliatin, a novel glucokinase activator, in type 2 diabetes

Lijiao Chen et al. Endocrine. .

Abstract

Purpose: To investigate the potential factors influencing blood glucose levels in patients with type 2 diabetes (T2DM) during the initial administration of dorzagliatin.

Methods: In this study, we enrolled 173 hospitalized patients diagnosed with T2DM who received dorzagliatin treatment. The mean fasting blood glucose (MFBG) and mean postprandial blood glucose (MPBG) were determined by recording the fasting and 2-h postprandial blood glucose for three consecutive days following dorzagliatin administration. Comprehensive data were collected, including demographic characteristics, anthropometric measurements, metabolic profiles, organ function parameters, and detailed information on glucose-lowering medications. Multiple linear regression analysis was utilized to identify independent predictors of MFBG and MPBG.

Results: MFBG in T2DM patients treated with dorzagliatin was positively correlated with the duration of diabetes (β = 0.241, P = 0.002), baseline fasting plasma glucose (FPG) (β = 0.198, P = 0.010), and total cholesterol (TC) (β = 0.166, P = 0.036). MPBG was negatively associated with metformin use (β = -0.286, P = 0.012), and the risk of hypoglycemia was also associated with metformin use (OR = 4.25, P = 0.021) rather than insulin or other antidiabetic agents. In addition, MPBG was positively related to the duration of diabetes (β = 0.204, P = 0.008), and aspartate aminotransferase (AST) (β = 0.186, P = 0.008).

Conclusion: Blood glucose levels of T2DM patients during dorzagliatin initial treatment are positively correlated with diabetes duration, suggesting greater efficacy of dorzagliatin in patients with shorter disease duration. Metformin may enhance the glucose-lowering efficacy of dorzagliatin but also increase the risk of hypoglycemia. Furthermore, factors like baseline FPG, TC and AST also influence outcomes.

Keywords: Blood glucose; Dorzagliatin; Hypoglycemia; Metformin.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standards. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Shanghai Pudong Hospital (WZ-010). Informed consent was obtained from all participants before their enrollment. All data utilized in this investigation were anonymized before their utilization. Conflict of interest: The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. H. Sun et al., IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119 (2022). - DOI - PubMed
    1. Y. Abu Aqel et al., Glucokinase (GCK) in diabetes: from molecular mechanisms to disease pathogenesis. Cell. Mol. Biol. Lett. 29, 120 (2024). - DOI - PubMed - PMC
    1. F.M. Matschinsky, Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes 39, 647–652 (1990). - DOI - PubMed
    1. J.F. Caro et al., Liver glucokinase: decreased activity in patients with type II diabetes. Horm. Metab. Res. 27, 19–22 (1995). - DOI - PubMed
    1. R.A. Haeusler et al., Decreased expression of hepatic glucokinase in type 2 diabetes. Mol. Metab. 4, 222–226 (2015). - DOI - PubMed

LinkOut - more resources